Companion Animal Postoperative Pain Management Therapeutics Market to Grow with a CAGR of 7.00% through 2028

The rise in orthopedic and dental surgeries and a growing awareness of pet health is expected to drive the Global Companion Animal Postoperative Pain Management Therapeutics Market growth in the forecast period, 2024-2028.

According to TechSci Research report, “Companion Animal Postoperative Pain Management Therapeutics Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Companion Animal Postoperative Pain Management Therapeutics Market stood at USD 340.55 million in 2022 and is anticipated to grow with a CAGR of 7.00% in the forecast period, 2024-2028. This can be attributed to market data and research. Data and research play a crucial role in driving the growth of the global companion animal postoperative pain management therapeutics market. Organizations like the American Medical Association (AMA) monitor trends and provide reports, as mentioned in the introduction, showcasing the rise in clinic visits for dogs due to dental problems. Such reports not only shed light on the evolving needs of the market but also serve as a reference for stakeholders in the industry, guiding them in the development of innovative pain management products. Moreover, the global companion animal postoperative pain management therapeutics market faces challenges due to regulatory variations in different regions. A trend towards regulatory harmonization is emerging, which aims to streamline the approval process for new medications across borders. This trend is expected to expedite the introduction of innovative pain management solutions.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Companion Animal Postoperative Pain Management Therapeutics Market.”

The market is poised for further growth, driven by increasing disposable income in both developing and developed nations. For instance, as outlined in a report from the American Veterinary Medical Association (AVMA), pet owners in the United States spent approximately USD 15.42 billion on veterinary surgeries in 2017. During the same year, around 20 million dogs underwent surgical procedures, with approximately 5 million of them experiencing postoperative pain. The rising adoption of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is expected to boost the market for therapeutics aimed at managing postoperative pain in companion animals. This trend is a result of heightened concerns among pet owners and a decreased reliance on off-label human pain relievers. The unmet demand for extended-release local anesthetics for small animals is driving industry players to develop such drugs. For example, In situ Biologics' AniGel SR demonstrated 72-hour efficacy in pre-clinical studies for postoperative pain management, pending approval from the U.S. Food and Drug Administration (FDA), which is expected to contribute to increased market revenue in the coming years. According to data from the Animal Cancer Foundation, there were approximately 65 million dogs and 32 million cats in the U.S. in 2017. The growing number of veterinary hospitals and pet clinics is propelling the market for therapeutics to manage postoperative pain in companion animals. As reported by the American Veterinary Medical Association (AVMA), private practices catering to small animals in the U.S. increased by 14% in 2018. The use of opioids as postoperative pain relievers is hampered by stringent regulations affecting both human and animal use. In 2014, about 40% of U.S. veterinarians used to prescribe opioids for perioperative treatment in animals. In 2017, the U.S. FDA established guidelines for the safe use of opioids in pet animals, necessitating veterinarians to obtain Drug Enforcement licenses before prescribing opioids to animals. According to an AVMA survey, in 2018, 44% of opioids were being misused or abused by pet owners, and 11% were intentionally harming their pets with opioids. These factors are expected to constrain the growth of opioids while driving revenue for other postoperative pain relievers in the near future.

The Global Companion Animal Postoperative Pain Management Therapeutics Market is segmented into product, animal type, regional distribution, and company.

Based on its product, the NSAIDs category asserted its dominance in the market in 2022, primarily due to the widespread availability of these products. These medications are primarily employed to manage inflammation and post-surgery pain. NSAIDs offer a cost-effective alternative compared to opioids and anesthetics, which is consequently boosting their revenue. Prominent examples of frequently used NSAIDs for post-surgical pain include Rimadyl (Injectable), Metacam, Deramaxx, and Previcox. Market participants are actively pursuing the development of innovative NSAIDs tailored for peri-operative pain management. Notably, Elanco secured approval for Onsior in May 2016, specifically designed for postoperative pain management following soft tissue surgery in dogs.

The anesthetics segment is anticipated to exhibit consistent growth throughout the projected period. Lidocaine and bupivacaine are commonly utilized anesthetics. According to a report from the AVMA, around 5 million dogs experienced post-surgical pain in 2016. The demand for controlled-release or long-acting local anesthetics is on the rise, as pet owners increasingly prefer to bring their pets home after surgical procedures. In 2016, Aratana Therapeutics introduced Nocita, designed for postoperative pain management, with the capability to effectively alleviate pain for up to 72 hours.

Based on animal type, the Canine sector secured the largest market share in 2022, primarily due to a notable increase in surgical procedures. The growing prevalence of chronic ailments in dogs serves as a key driver for this trend. Surgeries such as dental procedures, hip dysplasia treatments, cataract operations, wound repairs, and neutering are among the most frequently performed procedures on dogs, all necessitating postoperative care. Furthermore, the rising adoption of dogs as companion animals in households across both developed and developing nations is expected to further stimulate market growth.

On the other hand, the Feline segment is poised for a consistent CAGR during the forecast period. This steady growth is attributable to a growing concern among cat owners regarding the management of postoperative pain in their feline companions. Additionally, the increase in surgical interventions performed on cats plays a significant role in propelling this segment's growth. Common health issues in cats include urinary tract infections, bladder stones, kidney diseases, dental and ocular problems, and ear infections. The surge in cat adoption in European and Asian countries is contributing to this expansion. Notably, in 2018, Europe boasted a feline population of 102.69 million, surpassing the canine population of 84.91 million. The availability of favorable insurance policies is also projected to further augment growth within this segment.

Major companies operating in Global Companion Animal Postoperative Pain Management Therapeutics Market are:

• Zoetis Inc
• Bayer AG
• Merck Animal Health
• Elanco Animal Health Inc
• Norbrook Laboratories Ltd
• Ceva Sante Animale SA
• Dechra Pharmaceuticals PLC

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The global companion animal postoperative pain management therapeutics market is undergoing a transformative phase with a focus on personalized pain management, advanced pharmaceutical innovations, the integration of alternative therapies, telemedicine and remote monitoring, ethical and environmental considerations, regulatory harmonization, and enhanced pain assessment tools. These upcoming trends promise to provide more effective, compassionate, and sustainable pain management solutions, ensuring the well-being and comfort of our beloved companion animals as the industry evolves to meet their evolving needs,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“Companion Animal Postoperative Pain Management Therapeutics Market By Product (NSAIDs, Anesthetics, Opioids, Others), By Animal Type (Canine, Feline), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global Companion Animal Postoperative Pain Management Therapeutics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Companion Animal Postoperative Pain Management Therapeutics Market.

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +13322586602

Email: [email protected]               

Website: www.techsciresearch.com